As anti-aging NAD+ drips capture the attention of A-list celebrities, doctors explain the science behind the wellness treatment.

A center for intravenous, or IV, vitamin therapy is opening in Houston's West University neighborhood in early 2025.

Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have ...

In a significant advancement for cancer care, the U.S. Food and Drug Administration (FDA) has approved an injectable version ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

SAGE-689 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Becomes the first subcutaneously administered PD-1 inhibitor.

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...